secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2026-09-30T20:20:20+00:00
Accession:  0001159036-26-000128
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4.1-flash:cloud@v2

Halozyme elects James Daly to board, term runs through 2029 annual meeting
--------------------------------------------------------------------------

- James Daly was elected to Halozyme Therapeutics' Board of Directors on September 28, 2026.
- Daly's director term ends at the company's annual meeting of stockholders in 2029; he was not assigned to any board committee.
- Daly will receive compensation under Halozyme's non-employee director program, including cash retainers and restricted stock and stock option awards.
- Halozyme said there are no arrangements or understandings for Daly's election and no related person transactions between him and the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903626000128/0001159036-26-000128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903626000128/halo-20260928.htm
  HTML page:      https://secwatch.observer/filing/0001159036-26-000128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer